Valuation: DMS

Market Cap 23.28M 26.06M 21.65M 19.7M 37.19M 2.52B 37.35M 261M 102M 1.29B 97.87M 95.73M 4.13B P/E 2026 *
30x
P/E 2027 * 9x
Enterprise Value 38.68M 43.31M 35.98M 32.73M 61.79M 4.19B 62.06M 433M 170M 2.14B 163M 159M 6.86B EV / Sales 2026 *
0.68x
EV / Sales 2027 * 0.47x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 17/07/2022
Director of Finance/CFO - 31/12/2021
Chief Tech/Sci/R&D Officer - 31/12/2018
Director TitleAgeSince
Chairman 53 17/07/2022
Director/Board Member 52 15/06/2025
Director/Board Member - 23/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 26.06M
+0.93%+0.49%+25.38%+32.63% 243B
+1.08%+2.69%+8.57%+0.50% 155B
+2.06%+8.17%-1.31%+42.35% 150B
+1.64%+0.31%-55.21%-20.58% 61.93B
+1.15%+0.07%+15.24%+16.87% 49.12B
+2.30%+3.38%-17.09%-19.05% 48.78B
+1.41%+1.65%+24.83%+50.53% 48.08B
+3.96%+8.34%+3.33%+38.46% 47.95B
+1.08%+2.01%+31.05%+61.37% 42.62B
Average +1.56%+2.82%+3.86%+22.57% 94.01B
Weighted average by Cap. +1.51%+2.75%+7.65%+23.49%

Financials

2026 *2027 *
Net sales 56.8M 63.6M 52.84M 48.06M 90.74M 6.16B 91.14M 636M 249M 3.14B 239M 234M 10.07B 65.9M 73.79M 61.3M 55.76M 105M 7.14B 106M 738M 289M 3.64B 277M 271M 11.68B
Net income 800K 896K 744K 677K 1.28M 86.69M 1.28M 8.96M 3.51M 44.2M 3.36M 3.29M 142M 2.6M 2.91M 2.42M 2.2M 4.15M 282M 4.17M 29.11M 11.41M 144M 10.93M 10.69M 461M
Net Debt 15.4M 17.24M 14.33M 13.03M 24.6M 1.67B 24.71M 172M 67.56M 851M 64.75M 63.34M 2.73B 8M 8.96M 7.44M 6.77M 12.78M 867M 12.84M 89.57M 35.09M 442M 33.64M 32.9M 1.42B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - DMS